Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Travere Therapeutics will present nine data sets, including five oral presentations, on FILSPARI (sparsentan) at ASN Kidney Week 2026 in Denver, October 21-25. Final SPARTAN Phase 2 data showed 75% complete proteinuria remission and near-physiologic eGFR decline over two years with first-line FILSPARI use in IgA nephropathy. A post hoc DUPLEX analysis in FSGS patients without nephrotic syndrome showed roughly 3x higher complete proteinuria remission rates (20% vs 6%) and lower kidney failure rates (2% vs 8%) versus maximum labeled dose irbesartan.
Key figures
- Drug Name
- FILSPARI (sparsentan)
- Phase Of Trial
- Phase 2 SPARTAN; Phase 3 DUPLEX
- Duplex n
- 254
- Presentations
- 9
- Duplex kidney failure
- 2% vs 8%
- Duplex upcr reduction
- 48% vs 27% (irbesartan)
- Duplex complete remission
- 20% vs 6%
- Spartan chronic egfr slope
- -1.11 mL/min/1.73 m2/year
- Spartan complete proteinuria remission
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.